(lp0
S"Aviragen Therapeutics Inc : What's Next? Insider Financial - Feb 16, 2017 Aviragen Therapeutics Inc  is not having a good week. The company just put out data from a phase 2 study of its lead development asset, and has taken a close to 40% hit on the news.Aviragen Therapeutics Inc  Lowered to Neutral at HC Wainwright - The Cerbat Gem"
p1
aS'Aviragen Therapeutics slammed again by its second trial failure in days, this ... Endpoints News - Feb 13, 2017 In back-to-back setbacks, Aviragen Therapeutics $AVIR says that its lead drug vapendavir flunked a Phase IIb in moderate to severe asthmatics with a rhinovirus infection.'
p2
aS'The Analysts Anticipate Aviragen Therapeutics Inc  to Post  EPS Petro Global News 24 - 3 hours ago Shares of Aviragen Therapeutics Inc  have earned an average broker rating score of 0.00  from the two brokers that cover the company, Zacks Investment Research reports.Can This Stock Gain Any Traction: Aviragen Therapeutics, Inc. ? - Morgan Research'
p3
aS'Biota Pharmaceuticals Is Now Aviragen Therapeutics Seeking Alpha - Apr 27, 2016 Subsequent to our last update on Aviragen Therapeutics, the company has been busy attending and presenting at industry conferences.'
p4
aS"Aviragen Therapeutics'  CEO Joseph Patti on Q2 2017 Results - Earnings ... Seeking Alpha - Feb 3, 2017 Good day, ladies and gentlemen, and welcome to the Aviragen Therapeutics, Inc. Second Quarter 2017 Financial Results Conference Call.Aviragen Hits 52-Week Low on Drug Failure  - Investopedia"
p5
aS'0.63 MarketWatch - May 4, 2016 Aviragen Therapeutics Inc. Watchlist CreateAVIRAlert. Closed. Last Updated: Mar 21, 2017 3:57 p.m.. $ 0.63. -0.03 -4.55%.'
p6
aS"Mid-Day Market Update: RetailMeNot Gains After Strong Q4 Results; Aviragen ... Benzinga - Feb 14, 2017 Aviragen Therapeutics Inc  shares dropped 37 percent to $0.681 after the company reported top-line results from its Phase 2b SPIRITUS trial of vapendavir.4 Stocks That Are Breaking Hearts on Valentine's Day - 24/7 Wall St."
p7
aS'Ticker Watch: Technical Views on Shares of Aviragen Therapeutics Inc  Rives Journal - Mar 21, 2017 Aviragen Therapeutics Inc  currently has a 14-day Commodity Channel Index  of 19.57. Despite the name, CCI can be used on other investment tools such as stocks.'
p8
aS'BRIEF-Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS ... Reuters - Feb 13, 2017 Feb 13 Aviragen Therapeutics Inc. * Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS trial of Vapendavir.'
p9
aS"Aviragen Therapeutics'  CEO Dr. Joseph Patti on Q4 2016 Results ... Seeking Alpha - Sep 14, 2016 I would like to welcome you to the Aviragen Therapeutics conference call and webcast to review the Company's fourth quarter and fiscal yearend 2016 earnings results to provide an update on recent pipeline and corporate developments."
p10
a.